[REVISION HISTORY]

Brazil HIV prevention technology incorporation

2 recorded revisions of this situation.

What changed

2026-09-30 12:14 UTC → 2026-10-04 04:24 UTC · added ~~removed~~

Brazil’s National Commission for the Incorporation of Technologies in the SUS (Conitec) has issued a preliminary favorable recommendation to include injectable cabotegravir in the Unified Health System (SUS). This long-acting medication, produced by GSK, is intended to expand HIV prevention options rather than replace existing oral Pre-Exposure Prophylaxis (PrEP). The Ministry of Health intends to prioritize the injectable version for highly vulnerable individuals who encounter social or logistical barriers to the consistent use of oral PrEP. Unlike the daily oral PrEP pills currently used by over 150,000 people in Brazil, this injectable version offers protection that lasts for two months. The administration schedule involves monthly injections for the first two months, followed by doses every two months. Clinical studies indicate a protection rate exceeding 99%. While official estimates suggest the drug could arrive in the second half of 2026, GSK officials have indicated that if a positive recommendation is received from Conitec in October, they will attempt to make the medication available as early as this year. The drug has already received approval from Anvisa for three years. Unlike the daily oral PrEP pills currently used by over 150,000 people in Brazil, this injectable version offers protection that lasts for two months. The administration schedule involves monthly injections for the first two months, followed by doses every two months. Clinical studies indicate a protection rate exceeding 99%.

Versions

Select a version to see what changed compared to the one before it.